10x Genomics (NASDAQ:TXG) Announces Quarterly Earnings Results, Misses Expectations By $0.08 EPS

10x Genomics (NASDAQ:TXG) issued its earnings results on Wednesday. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08), Zacks reports. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. 10x Genomics updated its FY 2025 guidance to EPS.

10x Genomics Stock Up 1.5 %

TXG traded up $0.18 during trading on Wednesday, reaching $12.00. The stock had a trading volume of 4,201,812 shares, compared to its average volume of 2,328,019. 10x Genomics has a 1-year low of $11.55 and a 1-year high of $51.22. The firm has a market capitalization of $1.45 billion, a price-to-earnings ratio of -7.84 and a beta of 1.85. The stock has a 50 day moving average of $14.90 and a two-hundred day moving average of $17.50.

Analyst Ratings Changes

Several brokerages recently issued reports on TXG. Barclays cut their price target on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Monday. Weiss Ratings reiterated a “sell (e+)” rating on shares of 10x Genomics in a research note on Saturday, February 1st. Citigroup lowered their price target on shares of 10x Genomics from $35.00 to $23.00 and set a “buy” rating for the company in a research report on Wednesday, October 30th. The Goldman Sachs Group cut their price objective on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating on the stock in a research report on Wednesday, October 30th. Finally, Morgan Stanley decreased their target price on shares of 10x Genomics from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, January 13th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $23.79.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.